COMMUNIQUÉS West-GlobeNewswire

AMAG Pharmaceuticals to Present at Needham 18th Annual Healthcare Conference
02/04/2019
WALTHAM, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Ted Myles, chief financial officer, will present at the Needham 18 th Annual Healthcare Conference in New [...]
HealthLynked Corp. Reports Full Year 2018 Results with 7% increase in Revenue
02/04/2019
NAPLES, Fla., April 02, 2019 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB: HLYK ), late yesterday reported its results for the full year 2018. Full Year 2018 Highlights: 7% increase in revenue to $2.3 million compared [...]
Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B
02/04/2019
Currently enrolling individuals with severe hemophilia B SOUTH SAN FRANCISCO, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced the initiation of enrollment in a Phase [...]
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
02/04/2019
SOUTH SAN FRANCISCO, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in London [...]
Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases
02/04/2019
– $175 million committed from investors in private placement offering – – Trading of CYCN begins on Nasdaq today – CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today [...]
Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
02/04/2019
NORCROSS, Ga., April 02, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin, the Company’s [...]
AACR 2019 Presentations Highlight CX-2009, a First-In-Class Probody Drug Conjugate Targeting Novel Tumor Antigen, CD166
02/04/2019
- PROCLAIM-CX-2009 Dose Escalation Study Demonstrates Anti-Tumor Activity in Multiple Tumor Types - - Preclinical Studies Suggest Role of CD166 Expression Level in Anti-Cancer Activity and Potential for Combination of [...]
Imagin Medical Completes Assembly of i/Blue™ Imaging System Functional Unit
02/04/2019
VANCOUVER, British Columbia and BOSTON, April 02, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that it reached [...]
Leading Health Expert Bryce Wylde Joins Brain Armor® Advisory Board Focusing on Education and Innovation
02/04/2019
Brookfield, WI, April 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Trident Brands Inc. (OTCQB: TDNT) today announced that leading health expert, functional medicine clinician, and media personality Bryce Wylde has [...]
Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019
02/04/2019
--CDX-1140 has achieved good systemic exposure without reaching a maximum tolerated dose to date-- --Addition of dendritic cell growth factor CDX-301 enhances cytokine response without additive toxicity at dose levels [...]
ALRT Aims For Dramatic Improvements in the Standard of Care For Diabetes
02/04/2019
Current treatment can be more effective with modern diabetes technology RICHMOND, Va., April 02, 2019 (GLOBE NEWSWIRE) -- “Clinical inertia causes diabetes to deteriorate in millions of patients,” said Sidney Chan, CEO [...]
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
02/04/2019
PHILADELPHIA and OXFORD, United Kingdom, April 02, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data from two patients with [...]
Chembio Diagnostics Announces Agreement with Perseus Science to Advance Point-of-Care Concussion Test
02/04/2019
MEDFORD, N.Y., April 02, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the company has entered into [...]
Synthorx to Present at H.C. Wainwright Global Life Sciences Conference in London
02/04/2019
SAN DIEGO, April 02, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics [...]
IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA
02/04/2019
SAINT LAURENT, Quebec, April 02, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced it has received a Complete Response Letter (“CRL”) [...]
NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
02/04/2019
AMES, Iowa, April 02, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207, a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin [...]
Foamix Announces Settlement of Litigation with Perrigo Relating to Finacea Foam
02/04/2019
REHOVOT, Israel and BRIDGEWATER, N.J., April 02, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing [...]
Cabaletta Bio Appoints Distinguished Immunotherapist and Cell Therapy Expert, Catherine Bollard, M.D., to its Board of Directors
02/04/2019
RADNOR, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, announced today the [...]
Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019
02/04/2019
Oral CD73 inhibitor enhances the effect of checkpoint blockade and chemotherapy SOUTH SAN FRANCISCO, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology [...]

Pages